The University of Southampton
University of Southampton Institutional Repository

One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular Q2 degeneration

One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular Q2 degeneration
One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular Q2 degeneration
Purpose: to investigate 1-year visual and anatomic outcomes of intravitreal aflibercept for neovascular age-related macular degeneration (nAMD) given at a fixed 8-weekly interval.

Methods: retrospective, single-practice data analysis from an electronic medical record system of 255 eyes (223 patients) with treatment-naïve nAMD receiving 8-weekly aflibercept.

Results: mean logarithm of the minimum angle of resolution best-corrected visual acuity (BCVA) improved from 0.66 at baseline to 0.50 at month 11 (Po0.0001). Mean central retinal thickness (CRT) decreased from 311µm at baseline to 211µm at month 11 (Po0.0001). Our mean VA gain of eight ETDRS letters was comparable to the VIEW 1 and VIEW 2 Trials’ results at the end of year 1. After loading at month 5, mean BCVA was 0.48 (Po0.0001), and mean CRT was 235 µm. At month 5, 143 eyes (56%) were inactive defined by the absence of macular haemorrhage and intraretinal fluid (IRF) and subretinal fluid (SRF) on optical coherence tomography, and 112 eyes (44%) remained active. At month 11, 136 eyes (53%) were inactive, and 119 eyes (47%) remained active. At month 11, 77% of inactive eyes after loading remained inactive, and 77% of the active eyes after loading remained active. At month 11, mean BCVA of the inactive group was 0.51, and mean BCVA of the active group was 0.48 (P = 0.54).

Conclusions: aflibercept administered by fixed dosing over 1 year improved VA and macular morphology in treatment-naïve eyes. Active lesions at month 11 do not have worse VA outcomes compared with inactive lesions. The macular status after loading is a reliable indicator of disease activity at the end of year 1
0950-222X
878-883
Lotery, Andrew
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Rufai, Sohaib
33ada28b-2d6c-479f-a012-6956f7e7ccbe
Almuhtaseb, Hussein
27fcdbb3-4784-483d-823c-c6dae6151578
Kanavati, S.
35f7f090-fd2a-4a09-823d-e5685f5d7b77
Lotery, Andrew
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Rufai, Sohaib
33ada28b-2d6c-479f-a012-6956f7e7ccbe
Almuhtaseb, Hussein
27fcdbb3-4784-483d-823c-c6dae6151578
Kanavati, S.
35f7f090-fd2a-4a09-823d-e5685f5d7b77

Lotery, Andrew, Rufai, Sohaib, Almuhtaseb, Hussein and Kanavati, S. (2017) One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular Q2 degeneration. Eye, 31, 878-883. (doi:10.1038/eye.2017.6).

Record type: Article

Abstract

Purpose: to investigate 1-year visual and anatomic outcomes of intravitreal aflibercept for neovascular age-related macular degeneration (nAMD) given at a fixed 8-weekly interval.

Methods: retrospective, single-practice data analysis from an electronic medical record system of 255 eyes (223 patients) with treatment-naïve nAMD receiving 8-weekly aflibercept.

Results: mean logarithm of the minimum angle of resolution best-corrected visual acuity (BCVA) improved from 0.66 at baseline to 0.50 at month 11 (Po0.0001). Mean central retinal thickness (CRT) decreased from 311µm at baseline to 211µm at month 11 (Po0.0001). Our mean VA gain of eight ETDRS letters was comparable to the VIEW 1 and VIEW 2 Trials’ results at the end of year 1. After loading at month 5, mean BCVA was 0.48 (Po0.0001), and mean CRT was 235 µm. At month 5, 143 eyes (56%) were inactive defined by the absence of macular haemorrhage and intraretinal fluid (IRF) and subretinal fluid (SRF) on optical coherence tomography, and 112 eyes (44%) remained active. At month 11, 136 eyes (53%) were inactive, and 119 eyes (47%) remained active. At month 11, 77% of inactive eyes after loading remained inactive, and 77% of the active eyes after loading remained active. At month 11, mean BCVA of the inactive group was 0.51, and mean BCVA of the active group was 0.48 (P = 0.54).

Conclusions: aflibercept administered by fixed dosing over 1 year improved VA and macular morphology in treatment-naïve eyes. Active lesions at month 11 do not have worse VA outcomes compared with inactive lesions. The macular status after loading is a reliable indicator of disease activity at the end of year 1

Text
ARTICLEproofreadfinal.pdf - Accepted Manuscript
Download (161kB)

More information

Accepted/In Press date: 10 January 2017
e-pub ahead of print date: 10 February 2017
Organisations: Faculty of Medicine

Identifiers

Local EPrints ID: 405432
URI: http://eprints.soton.ac.uk/id/eprint/405432
ISSN: 0950-222X
PURE UUID: 5611df37-0cdc-4c7f-afc7-274316f2e714
ORCID for Andrew Lotery: ORCID iD orcid.org/0000-0001-5541-4305

Catalogue record

Date deposited: 03 Feb 2017 11:33
Last modified: 07 Oct 2020 04:56

Export record

Altmetrics

Contributors

Author: Andrew Lotery ORCID iD
Author: Sohaib Rufai
Author: Hussein Almuhtaseb
Author: S. Kanavati

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×